Curis Inc.
| NASDAQ: CRIS | Healthcare / Biotechnology / USA |
| 1.06 | -0.0500 | -4.50% | Vol 804.68K | 1Y Perf -84.92% |
| Aug 16th, 2022 16:00 DELAYED |
| BID | 1.06 | ASK | 1.10 | ||
| Open | 1.11 | Previous Close | 1.11 | ||
| Pre-Market | - | After-Market | 1.09 | ||
| - - | 0.03 2.83% |
| Target Price | 10.00 | Analyst Rating | Moderate Buy 1.67 | |
| Potential % | 843.40 | Finscreener Ranking | ★★★★ 52.52 | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★★ 52.19 | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★★★★ 56.89 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 4.32 | Earnings Rating | Sell | |
| Market Cap | 97.32M | Earnings Date | 4th Aug 2022 | |
| Alpha | 0.03 | Standard Deviation | 0.66 | |
| Beta | 2.83 |
Today's Price Range 1.051.12 | 52W Range 0.70009.04 | 5 Year PE Ratio Range -6.60-2.90 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 1.92% | ||
| 1 Month | -5.36% | ||
| 3 Months | 22.76% | ||
| 6 Months | -67.68% | ||
| 1 Year | -84.92% | ||
| 3 Years | -47.26% | ||
| 5 Years | -87.82% | ||
| 10 Years | -95.05% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -63.49 | |||
ROE last 12 Months | -65.00 | |||
ROA (5Y Avg) | -12.86 | |||
ROA last 12 Months | -36.59 | |||
ROC (5Y Avg) | -73.79 | |||
ROC last 12 Months | -57.30 | |||
Return on invested Capital Q | -20.60 | |||
Return on invested Capital Y | -12.33 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.90 | ||||
| 1.70 | ||||
| 9.59 | ||||
| 36.40 | ||||
| -2.20 | ||||
| -0.51 | ||||
| 1.99 | ||||
| 0.68 | ||||
| -4 503 310.00 | ||||
| Forward PE | -1.91 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 9.00 | ||||
| 9.30 | ||||
| 0.05 | ||||
| 0.07 | ||||
| -12.30 | ||||
| Leverage Ratio | 1.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 96.00 | ||||
| -493.80 | ||||
| -492.30 | ||||
| -376.60 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 10.62M | ||||
| 0.12 | ||||
| 2.88 | ||||
| 4.09 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2022 | -0.17 | -0.17 | 0.00 |
| Q01 2022 | -0.17 | -0.18 | -5.88 |
| Q04 2021 | -0.13 | -0.15 | -15.38 |
| Q03 2021 | -0.13 | -0.12 | 7.69 |
| Q02 2021 | -0.11 | -0.12 | -9.09 |
| Q01 2021 | -0.09 | -0.11 | -22.22 |
| Q04 2020 | -0.07 | -0.11 | -57.14 |
| Q03 2020 | - | -0.11 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | -0.17 | -6.25 | Negative |
| 9/2022 QR | -0.17 | -6.25 | Negative |
| 12/2022 FY | -0.67 | -6.35 | Negative |
| 12/2023 FY | -0.60 | 7.69 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -0.17 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 804.68K |
| Shares Outstanding | 91.81K |
| Shares Float | 91.39M |
| Trades Count | 2.82K |
| Dollar Volume | 864.01K |
| Avg. Volume | 2.05M |
| Avg. Weekly Volume | 1.53M |
| Avg. Monthly Volume | 1.69M |
| Avg. Quarterly Volume | 2.94M |
Curis Inc. (NASDAQ: CRIS) stock closed at 1.06 per share at the end of the most recent trading day (a -4.5% change compared to the prior day closing price) with a volume of 804.68K shares and market capitalization of 97.32M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 28 people. Curis Inc. CEO is James E. Dentzer.
The one-year performance of Curis Inc. stock is -84.92%, while year-to-date (YTD) performance is -77.73%. CRIS stock has a five-year performance of -87.82%. Its 52-week range is between 0.7 and 9.04, which gives CRIS stock a 52-week price range ratio of 4.32%
Curis Inc. currently has a PE ratio of -1.90, a price-to-book (PB) ratio of 1.70, a price-to-sale (PS) ratio of 9.59, a price to cashflow ratio of 36.40, a PEG ratio of 2.32, a ROA of -36.59%, a ROC of -57.30% and a ROE of -65.00%. The company’s profit margin is -%, its EBITDA margin is -492.30%, and its revenue ttm is $10.62 Million , which makes it $0.12 revenue per share.
Of the last four earnings reports from Curis Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. Curis Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Curis Inc. is Moderate Buy (1.67), with a target price of $10, which is +843.40% compared to the current price. The earnings rating for Curis Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Curis Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Curis Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.82, ATR14 : 0.11, CCI20 : 42.95, Chaikin Money Flow : -0.09, MACD : 0.00, Money Flow Index : 47.94, ROC : 9.90, RSI : 39.38, STOCH (14,3) : 72.22, STOCH RSI : 0.86, UO : 55.20, Williams %R : -27.78), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Curis Inc. in the last 12-months were: James E. Dentzer (Sold 5 500 shares of value $17 150 )
Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
CEO: James E. Dentzer
Telephone: +1 617 503-6500
Address: 4 Maguire Road, Lexington 02421, MA, US
Number of employees: 28
TipRanks News for CRIS
Fri, 07 Jan 2022 16:25 GMT Curis (CRIS) Gets a Buy Rating from B.Riley Financial
- TipRanks. All rights reserved.
